Neurocrine Biosciences Review, Ingrezza May Become Pipeline-in-a-Product
<p>Analysts at Oppenheimer provided a review on <a href='https://financialmodelingprep.com/financial-summary/NBIX'>Neurocrine Biosciences, Inc. (NASDAQ:NBIX)</a>, hypothesizing that Ingrezza could become a pipeline-in-a-product.</p>
<p>The analysts are encouraged by Ingrezza's (1) positive Ph3 results in KINECT-HD to support an sNDA filing in H2/22 with potential FDA approval in H2/23 to treat chorea in Huntington Disease (HD), (2) registrational study for Adjunctive Treatment of Schizophrenia (ATS) with topline results expected 2023, and (3) registrational study for Dyskinesia of Cerebal Palsy (DCP) with topline results expected 2024.</p>

NASDAQ:NBIX